Rufat R Kuliev

City Clinical Hospital named after A.K. Eramishantsev, Moscow, Russia.

2 publications 2024 – 2025 ORCID
RussiaIschemic StrokeFibrinolytic AgentsTissue Plasminogen ActivatorThrombolytic Therapy

What does Rufat R Kuliev research?

Rufat R Kuliev studies the impact of Revelise (alteplase) on patients suffering from ischemic stroke, a condition caused by blocked blood flow to the brain. By conducting extensive research, he aims to determine how well this treatment works in everyday medical practice, particularly among older patients and those with other health complications. His work evaluates the medication's ability to lessen disabilities caused by strokes and improve patients' quality of life.

Key findings

  • In a study of 2,202 people, nearly 50% (49.9%) had good outcomes upon discharge after receiving Revelise for ischemic strokes.
  • After 90 days, the percentage of patients with good outcomes increased to 66.4%, indicating the treatment's long-term effectiveness.
  • The research included a diverse group of patients, showing that Revelise is effective even in elderly individuals and those with additional health issues.

Frequently asked questions

Does Dr. Kuliev study ischemic stroke?
Yes, Dr. Kuliev focuses on treating ischemic stroke using Revelise and evaluates its effectiveness.
What treatments has Dr. Kuliev researched?
He has researched the medication Revelise (alteplase) for treating ischemic strokes.
Is Dr. Kuliev's work relevant to older stroke patients?
Yes, his research specifically includes older patients and shows positive results in their treatment outcomes.

Publications in plain English

[Thrombolytic Therapy for Ischemic Stroke with Revelise: Results of a Two-Year Follow-Up in the International PRIMA Study].

2025

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova

Shamalov NA, Khasanova DR, Marchenko SV, Soldatov MA, Azarova AG +46 more

Plain English
This study looked at how well and safely Revelise (alteplase), a medication for treating ischemic stroke (IS), works in real-life situations. It involved 2,202 patients, mostly around 68 years old, and found that nearly half (49.9%) of them had good outcomes when discharged, rising to 66.4% after 90 days. The results showed that Revelise effectively reduces stroke-related disabilities, even in older patients and those with other health issues. Who this helps: This benefits patients who suffer from ischemic strokes and the doctors treating them.

PubMed

Comparative Analysis of High-Frequency and Low-Frequency Transcutaneous Electrical Stimulation of the Right Median Nerve in the Regression of Clinical and Neurophysiological Manifestations of Generalized Anxiety Disorder.

2024

Journal of clinical medicine

Al-Zamil M, Kulikova NG, Minenko IA, Shurygina IP, Petrova MM +5 more

Plain English
This study looked at two types of electrical stimulation therapy, known as high-frequency (HF-TENS) and low-frequency (LF-TENS), to treat generalized anxiety disorder (GAD). The researchers found that both therapies significantly reduced anxiety symptoms by about 42%, compared to only a 13.5% reduction from a fake treatment. LF-TENS was even more effective, showing a 51% better improvement than HF-TENS, making it a promising option for home treatment due to its affordability and low side effects. Who this helps: This benefits patients with generalized anxiety disorder seeking effective and safe treatment options.

PubMed

Publication data sourced from PubMed . Plain-English summaries generated by AI. Not medical advice.